fbpx
Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Archive

Curettage and cryosurgery – effective for the most common skin cancer

Written by | 16 Jul 2023

The combination of curettage and cryosurgery is a safe and effective treatment method for the most common form of skin cancer, basal cell carcinoma. A study from the… read more.

Simple laser treatments may help prevent nonmelanoma skin cancer

Written by | 23 Jan 2023

New research indicates that simple laser treatments to the skin may help to prevent the development of basal cell carcinoma and squamous cell carcinoma, which are collectively known… read more.

FDA approves Libtayo as first immunotherapy indicated for patients with advanced basal cell carcinoma – Sanofi

Written by | 19 Feb 2021

The FDA has approved the PD-1 inhibitor Libtayo (cemiplimab-rwlc) from Sanofi as the first immunotherapy indicated for patients with advanced basal cell carcinoma (BCC) previously treated with a… read more.

Libtayo (cemiplimab) for advanced basal cell carcinoma

Written by | 21 Jul 2020

Article written by Christine Clark At present there are no approved treatments for advanced basal cell carcinoma, a condition that is estimated to affect about 20,000 US patients… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.